Harmony Biosciences (NASDAQ:HRMY – Get Free Report) and PainReform (NASDAQ:PRFX – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.
Profitability
This table compares Harmony Biosciences and PainReform’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Harmony Biosciences | 18.88% | 20.06% | 14.15% |
| PainReform | N/A | N/A | N/A |
Risk & Volatility
Harmony Biosciences has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, PainReform has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.
Insider & Institutional Ownership
Valuation and Earnings
This table compares Harmony Biosciences and PainReform”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Harmony Biosciences | $868.45 million | 2.52 | $158.69 million | $3.08 | 12.18 |
| PainReform | $20,000.00 | 35.62 | -$5.02 million | ($736.66) | -0.00 |
Harmony Biosciences has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations and price targets for Harmony Biosciences and PainReform, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Harmony Biosciences | 1 | 4 | 6 | 0 | 2.45 |
| PainReform | 1 | 0 | 0 | 0 | 1.00 |
Harmony Biosciences presently has a consensus target price of $47.44, indicating a potential upside of 26.48%. Given Harmony Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Harmony Biosciences is more favorable than PainReform.
Summary
Harmony Biosciences beats PainReform on 11 of the 14 factors compared between the two stocks.
About Harmony Biosciences
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
About PainReform
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
